Novavax is a clinical-stage biopharmaceutical company focused on developing recombinant vaccines to address a range of infectious diseases. Co.'s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Co.'s product pipeline targets a range of infectious diseases and its vaccine candidates are in or have completed clinical trials that target pandemic influenza, seasonal influenza and respiratory syncytial virus. Further, CPL Biologics Private Limited, Co.'s joint venture company in India, is developing a rabies vaccine candidate.

View SEC Filings from NVAX instead.
Filers who had this stock in their top 10: 0
13F Filers holding this stock: 170
Aggregate shares on 12/31/2015: 204,345,992
Aggregate shares on 09/30/2015: 195,200,704
Percent change: 4.69%
Funds creating new positions: 30
Funds Adding to an existing position: 65
Funds closing out their position: 47
Funds reducing their position: 48
View recent insider trading info

13F Filers holding this stock

Quarter 1: Refresh

Changes in Holdings:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Schedule 13D and 13G filings submitted since 12/31/2015

Subscription required

Click here to report any possible errors with this stock listing.

Elevate your investments

or Learn more